Remove

Doc code: IDS Doc description: Information Disclosure Statement (IDS) Filed

Approved for use through 07/31/2012, OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10521410	
	Filing Date		2005-01-18	
NFORMATION DISCLOSURE	First Named Inventor		Ullrich et al.	
STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Art Unit		1642	
	Examiner Name	Peter	er J. Reddig	
	Attorney Docket Numb	er	2923-679	

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	ate	Name of Pate of cited Docu	entee or Applicant ment	Releva	,Columns,Lines where ant Passages or Releve s Appear	
/PR/	1	5468634	A1	1995-11	I-21	Liu				
If you wis	h to ad	d additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUBI	LICATIONS		Remove	
Examiner Initial*	Cite N	Publication Number	Kind Code ¹	Publica Date	ition	Name of Pate of cited Docu	entee or Applicant ment	Releva	,Columns,Lines where ant Passages or Releva s Appear	
	1									
If you wis	h to ad	d additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ade	buttor	Add	
				FOREIG	3N PA1	TENT DOCUM	ENTS		Remove	
Examiner Initial*		Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	or ,	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
/PR/	1	92/17608	wo			1992-10-15	Birchmeier, Walter			
/PR/	2	98/06692	wo			1998-02-19	Celgene Corporation	n		
/PR/	3	00/76309	wo		A2	2000-12-21	Vlaams Interunivers Instituut Voor Biote			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Application Number		10521410	_
	Filing Date		2005-01-18	_
	First Named Inventor Ullric		ich et al.	
	Art Unit		1642	
Not for submission under or or it 1.55)	Examiner Name	Peter	r J. Reddig	
	Attorney Docket Numb	er	2923-679	
			•	_

10521/110

/PR/	4	01/78778	wo	A1	2001-10-25	Vlaams Interuniversitair Instituut Voor Biotech.			
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
			NON-PATEN	NT LITE	RATURE DO	CUMENTS	Remove		
Examiner Initials*	miner Cite No linclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								
/PR/	1	BACHMEIER BEATRICE E ET AL. "Matrix metallioproteinases (MMPs) in breast cancer cell lines of different tumorigencity," ANTICANCER RESEARCH, vol. 21, no. 6A, November 2001 (2001-11), pages 3821-3828, XP008008514 ISSN: 0250-7005							
/PR/	2	ATTAR, E. C. ET AL: "AXI receptor tyrosine kinase expression in human breast cancer." BREAST CANCER RESEARCH AND TREATMENT, (OCT., 1997) VOL. 46, NO. 1, PP. 91 MEETING INFO.: 20TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM SAN ANTONIO REXAS, USA DECEMBER 3-6, 1997, October 1997 (1997-10), XP008006520 * abstract *							
/PR/	3	DODGE ZANTEK N. ET AL: "MCF-10A-NeoST: A new cell system for studying cell-ECM and cell-cell interactions in breast cancer." CLINICAL CANCER RESEARCH, 7/11 (3640-3648), November 2001 (2001-11), XP001074226 * page 3646, right-hand column, paragraph 5 - page 3647, left-hand column.*							
/PR/	4	FRIDELL YIH-WOEI C ET AL: "GAS8 induces AxI-medialed chemotaxis of vascular smooth muscle cells" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, BALTIMORE, MD, US, vol. 273, no. 12, 20 March 1998 (1998-03-20), pages 7123-7126, XP002154999 v ISSN: 0021-9258 * abstract J							
/PR/	5	WU CHEW-WUN ET AL: "Clinical significance of AXL kinase family in gastric cancer." ANTICANCER RESEARCH, 22 (2B) 1071-8., March 2002 (2002-03), - April 2002 (2002-04) XP008006835 * abstract * * page 1075, left-hand column, paragraph 2 - page 1076, left-hand column, paragraph 2							
/PR/	6	MERIC F. ET AL: "Expression profile of tyrosine kinases in breast cancer." CLINICAL CANCER RESEARCH, 8/2 (361-367)., February 2002 (2002-02), XP001074227 * abstract * page 366, left-hand column, paragraph 2							
/PR/	7	BERCLAZ G ET AL: "Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast." ANNALS OF ONCOLOGY, 12 (6) 819-24., June 2001 (2001-06), XP008006834 * abstract * * page 821, left-hand column, paragraph 2 - page 822, right-hand column, paragraph 1							
/PR/	8	SODIUM BUTYRATE IN	OVARIAN CARC ONDON, GB, vol	INOMA . 73, no.	CELLS" BRITIS 4, 1 February 1	ASIVENESS ARE REPRES H JOURNAL OF CANCER, 996 (1996-02-01), pages 43 aragraph 1; figure 3 *	NATURE		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10521410		
Filing Date		2005-01-18		
irst Named Inventor	Ullrich	Ullrich et al.		
Art Unit		1642		
Examiner Name	Peter J. Reddig			
Attorney Docket Number		2023.670		

		c.c todaig					
Examine	r Signa	ure /Peter Reddia/		Date Considered	02/11/2011		
			EXAMINER SIGNATURE	•			
If you wish to add additional non-patent literature document citation information please click the Add button Add							
/PR/	12	Domagala W et al: "Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction", American Journal of Pathology, Vol. 136, No. 1, 1990, pages 219-227, XP008006515, ISSN: 0002-9440 "abstract"					
/PR/	11	PEDROCCHI M ET AL. "EXPRESSION OF CA2+BINDING PROTEINS OF THE \$100 FAMILY IN MALIGNANT HUMAN BREAST-CANCER CELL LINES AND BIOPPY SAMPLES" INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY LNKD D01:10.1002/IJC.2910570513, vol. 57, no. 5, 1 June 1994 (1994-06-01), pages 684-690, XP001064960 ISSN: 0020-7136 " the whole document "					
/PR/	10	SASART TET AL: "Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6. Receptor byrosine kinase activation by laminin G-like domains." JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY-FOR EIOCHEMISTRY AND MOLECULAR BIOLOGY, INC., US LINKD DOI:10.1074/JEC.M207340200, vol. 277, no. 46, 15 November 2002 (2002-11-15), pages 44164-44170, XP001168602 ISSN: 0021-9258 *abstract*					
/PR/	9	TIO M ET AL: "EXPRESSION OF RE PEDIATRIC THYROID CARCINOMA US LNKD- DOI:10.1089/1050725023 971-975, XP008026096 ISSN: 1050-	AS AROUND CHERNOBYL" THYRO 120009303, vol. 12, no. 11, 1 Noven	OID, MARY ANN LIEE	BERT, NEW YORK, NY,		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.